GlobeNewswire

2024-10-30 10:18

Avance Clinical CEO and Asia Director Sign MOUs with Key Clinical Trial Sites in Korea around 2024 KoNECT

WAKE FOREST, N.C. and ADELAIDE, Australia , Oct. 29, 2024 (GLOBE NEWSWIRE) -- Avance Clinical, a leading full-service global Contract Research Organization (CRO) known for delivering high-quality, agile clinical research services, is proud to announce the signing of three significant Memorandums of Understanding (MOUs) with key Korean clinical sites during KoNECT 2024 conference.

Avance Clinical CEO Yvonne Lungershausen and Asia Regional Director Jessica Han, attended the KoNECT conference, and the three clinical sites to sign these partnerships, marking an important milestone in the company’s strategic expansion across the Asia-Pacific region.

Avance Clinical is a mid-sized CRO with a proven track record of swiftly advancing quality clinical biotech programs. The CRO is highly regarded among US-based biotechs which make up more than 80% of its clients.

Lungershausen stated, “These new MOUs further strengthen our mission to provide world-class services to international biotech clients. As Avance Clinical continues to grow its global footprint, these partnerships with respected institutions will further enhance our ability to offer flexible, efficient, and high-quality clinical trial services in the Asia-Pacific region.”

Jessica Han, based in Seoul, said, “With its highly sophisticated healthcare infrastructure and regulatory framework, South Korea offers an ideal environment for clinical trials. These MOU signings will not only solidify our collaborations with key institutions but also provide our clients with seamless access to high-quality clinical trial sites and patient populations in the region. We look forward to forging deeper connections and driving growth in Asia.”

The MOUs were signed with:

CHA University Bundang Medical Center an advanced 1,000 bed hospital with a focus on patient care, research and education. Designated as a Research-Driven Hospital, it is committed to delivering a stable research environment and infrastructure to support the latest research and state-of-the-art medical technology. This partnership with Avance Clinical will further the reach and impact the hospital has on healthcare development globally.
Signed on October 28, 2024

Young-Sang Kim, Director for CHA Global Clinical Trials Center (CHA University Bundang Medical Center) shared his enthusiasm for the collaboration, remarking, “Partnering with Avance Clinical presents a valuable opportunity to expand our clinical trial expertise, especially in early-phase research. We believe this collaboration will not only strengthen our capabilities but also enable us to offer cutting-edge therapeutic solutions that will impact patients on a global scale.”

Korea University Medicine (Seoul), is a leading academic and medical institution recognized for its robust clinical trial capabilities. This partnership aims to accelerate clinical research opportunities, leveraging Korea University Medicine’s expertise to drive the development of innovative therapeutics.
Signed on October 29, 2024

Hak Jun Kim, President for Medical Research & Business Foundation of Korea University Medicine expressed optimism about the partnership, stating, “We look forward to collaborating with Avance Clinical, a global CRO, and this MOU marks an important starting point to further enhance our unique strengths. We anticipate maintaining a close relationship to play a leading role in the clinical trial field.”

Dong-A University Hospital, Clinical Trial Center (Pusan) is known for its comprehensive clinical trial infrastructure and experienced research teams. The collaboration with Dong-A aims to deepen research ties, particularly in early-phase clinical trials, offering expanded opportunities for clients seeking to develop breakthrough therapies across multiple therapeutic areas.
Signed on October 30, 2024

Sung Yong Oh, Director of the Dong-A University Hospital, Clinical Trial Center expressed confidence in the newly formed collaboration, stating, “This partnership with Avance Clinical marks a pivotal moment for us. By working together, we can further enhance our research infrastructure and significantly contribute to global healthcare innovations. We are confident that this collaboration will accelerate the development of advanced medical technologies and treatments.”

The MoU signings and Avance Clinical’s participation in KoNECT reflect the company's ongoing commitment to expanding its global footprint. KoNECT 2024, co-hosted by the Korea National Enterprise for Clinical Trials (KoNECT) and the Ministry of Health and Welfare (MOHW), is a premier event for thought leaders and industry professionals to discuss innovations in clinical trials across the Asia-Pacific region.

About Avance Clinical
Avance Clinical is a leading Contract Research Organization (CRO) offering biotech companies faster, more flexible, and higher-quality clinical trial services. Avance Clinical is the largest premium full-service Australian headquartered CRO delivering quality clinical trials, with globally accepted data, in Australia, New Zealand, Asia, North America and Europe for international biotechs. With 30 years of experience, Avance Clinical supports clients with comprehensive clinical research services, specializing in early to late phase clinical trials. With experience across more than 250 indications, the CRO can deliver world-class results and high-quality internationally accepted data for FDA and EMA review.

The company is a recipient of the Frost & Sullivan Global & APAC CRO Market Leadership & Customer Value Leadership Awards for the past five years. Avance Clinical provides services from pre-clinical through to mid and late-phase clinical trials, including the benefit of Australia’s 43.5% government incentive and rapid start-up regulatory processes.

Leveraging cutting-edge technologies like Medidata, Oracle, and Medrio, Avance Clinical ensures the most effective trial processes for its clients, delivering high-quality data for FDA and EMA review.

For more information, visit Avance Clinical.

Find out more:

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/bfa483a0-4ec4-4a47-8390-433d09842bb0


Media Contact:
Avance Clinical
media@avancecro.com
Kate Thompson

Primary Logo

source: Avance Clinical

【香港好去處】2025去邊最好玩?etnet為你提供全港最齊盛事活動,所有資訊盡在掌握!► 即睇

人氣文章
最近7天
1
港股 | 蕭猷華:內地AI發展迅速,阿里巴巴股價看俏
2
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
3
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
4
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
5
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
6
一本萬利 | 2025年的五個「勿」(有片)
7
啟德體育園明天足球賽測試,4.4萬公僕參與涉逾400萬車馬費
8
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
9
高息定存 | 華僑銀行推新春港元定存優惠,88天或188天享3.68厘
10
PapaHome淘寶家具實體店22日開幕,選址尖沙咀中港城,料創100個就業機會
11
電騙 | 黃俊碩:多管齊下,防治內地留學生受騙
12
易經看世界 | 乙巳蛇年趨吉五招:言行注意甚麼?應遠離甚麼人?(有片)
13
洪灝專訪 | 淘寶衝擊巨大,港樓價未反映大周期拐點(有片)
14
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
15
習近平應約與特朗普通電話,特:冀盡快與習見面
16
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
17
專訪 | 關稅戰 | 香港物流協會副會長梁庭彰:美物流商停收包裹對跨境電商打擊重大
18
【FOCUS】螺絲殼裏做道場,DeepSeek致勝啟示
19
港股 | 午市前瞻 | iPhone SE難救中國市場 專家提醒比電已超買
20
大S | 台灣藝人徐熙媛因流感併發肺炎逝世,享年48歲
21
雷賢達觀點 | 香港篇:恒指年波幅料六千點,港須全面融入大灣區
22
高息定存 | 一周高息合集,蛇年定存金蛇起舞,1個月定存高達8厘
23
DeepSeek推出即上蘋果中國區榜首,能力直追OpenAI
24
收市短打 | 楊韻銳:港股升勢有成交配合 惟留意關鍵阻力位!
25
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
26
港股 | 蕭猷華:春節假後,恒指逐步上望21000點
27
特朗普就職 | 特朗普上台後行動列表
28
馬斯克明拆特朗普台,指其星際之門計劃「假大空」
29
【FOCUS】侵侵呼籲全球「降息」,日銀祭18年最激進加息
30
高息定存 | 富邦一周港元定存高達9.88厘,一個月4.88厘
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

Watch Trends 2024

北上食買玩

Art Month 2024

理財秘笈

流感高峰期

山今養生智慧

輕鬆護老